Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) had its price objective cut by stock analysts at Citizens Jmp from $166.00 to $160.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp‘s price target indicates a potential upside of 40.05% from the stock’s current price.
A number of other analysts have also recently weighed in on the stock. Canaccord Genuity Group set a $154.00 price objective on shares of Rhythm Pharmaceuticals in a report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research note on Thursday, October 15th. Deutsche Bank assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Friday, August 28th. They set a “hold” rating and a $120.00 target price for the company. National Bank Financial set a $160.00 target price on shares of Rhythm Pharmaceuticals in a research report on Wednesday, August 5th. Finally, Guggenheim raised their price target on shares of Rhythm Pharmaceuticals from $143.00 to $147.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Eighteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $141.67.
Check Out Our Latest Report on Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Trading Down 2.2%
RYTM traded down $2.55 during trading on Friday, reaching $114.25. 283,859 shares of the company were exchanged, compared to its average volume of 865,437. The stock has a market cap of $7.92 billion, a P/E ratio of -39.34 and a beta of 2.17. The firm has a 50 day moving average of $97.93 and a 200 day moving average of $97.65. Rhythm Pharmaceuticals has a 52 week low of $74.50 and a 52 week high of $122.20.
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported ($0.61) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.10. Rhythm Pharmaceuticals had a negative return on equity of 171.16% and a negative net margin of 69.03%. The company had revenue of $92.13 million for the quarter, compared to analysts’ expectations of $85.56 million. During the same period last year, the business posted ($0.82) earnings per share. The firm’s quarterly revenue was up 79.6% compared to the same quarter last year. As a group, analysts forecast that Rhythm Pharmaceuticals will post -4.90 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Rhythm Pharmaceuticals news, Director Christophe Jean sold 10,000 shares of the business’s stock in a transaction dated Tuesday, November 17th. The shares were sold at an average price of $109.66, for a total transaction of $1,096,600.00. Following the sale, the director directly owned 11,712 shares in the company, valued at approximately $1,284,337.92. The trade was a 46.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Hunter Smith sold 62,774 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $105.46, for a total transaction of $6,620,146.04. Following the completion of the sale, the chief financial officer directly owned 114,024 shares of the company’s stock, valued at approximately $12,024,971.04. This represents a 35.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 122,774 shares of company stock worth $12,850,246. 5.90% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Rhythm Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in RYTM. GAMMA Investing LLC lifted its position in Rhythm Pharmaceuticals by 36.3% in the second quarter. GAMMA Investing LLC now owns 364 shares of the company’s stock worth $40,000 after purchasing an additional 97 shares during the period. Nisa Investment Advisors LLC boosted its stake in Rhythm Pharmaceuticals by 9.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the company’s stock valued at $155,000 after purchasing an additional 136 shares in the last quarter. ProShare Advisors LLC boosted its stake in Rhythm Pharmaceuticals by 1.9% during the 3rd quarter. ProShare Advisors LLC now owns 9,653 shares of the company’s stock valued at $919,000 after purchasing an additional 177 shares in the last quarter. Cim Investment Management Inc. increased its position in shares of Rhythm Pharmaceuticals by 7.2% during the 2nd quarter. Cim Investment Management Inc. now owns 3,209 shares of the company’s stock valued at $356,000 after purchasing an additional 216 shares during the period. Finally, Inspire Investing LLC increased its position in shares of Rhythm Pharmaceuticals by 7.9% during the 3rd quarter. Inspire Investing LLC now owns 3,688 shares of the company’s stock valued at $351,000 after purchasing an additional 271 shares during the period.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts, and its work centers on the melanocortin-4 receptor pathway, which helps regulate hunger and energy balance. Its commercial product, IMCIVREE (setmelanotide), is approved in the United States and Europe for certain forms of genetically defined obesity, including obesity associated with Bardet-Biedl syndrome and specific gene deficiencies.
Further Reading
- Five stocks we like better than Rhythm Pharmaceuticals
- Apple’s Rare Samsung Memory Plan Could Solve One Problem and Create Another
- Palo Alto Networks’ Q1 Beat Gives Its Stock Rally Another Reason to Run
- Airfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter Test
- Hard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
